GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » EV-to-Revenue

PharmX Technologies (ASX:PHX) EV-to-Revenue : 2.08 (As of May. 15, 2024)


View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PharmX Technologies's enterprise value is A$6.40 Mil. PharmX Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$3.08 Mil. Therefore, PharmX Technologies's EV-to-Revenue for today is 2.08.

The historical rank and industry rank for PharmX Technologies's EV-to-Revenue or its related term are showing as below:

ASX:PHX' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.2   Med: 1.25   Max: 3.82
Current: 2.08

During the past 13 years, the highest EV-to-Revenue of PharmX Technologies was 3.82. The lowest was -0.20. And the median was 1.25.

ASX:PHX's EV-to-Revenue is ranked worse than
54.31% of 661 companies
in the Healthcare Providers & Services industry
Industry Median: 1.87 vs ASX:PHX: 2.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-15), PharmX Technologies's stock price is A$0.03. PharmX Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.01. Therefore, PharmX Technologies's PS Ratio for today is 6.00.


PharmX Technologies EV-to-Revenue Historical Data

The historical data trend for PharmX Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies EV-to-Revenue Chart

PharmX Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 1.69 3.60 1.25 1.55

PharmX Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.25 - 1.55 -

Competitive Comparison of PharmX Technologies's EV-to-Revenue

For the Health Information Services subindustry, PharmX Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmX Technologies's EV-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's EV-to-Revenue falls into.



PharmX Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

PharmX Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6.404/3.075
=2.08

PharmX Technologies's current Enterprise Value is A$6.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$3.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmX Technologies  (ASX:PHX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

PharmX Technologies's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.03/0.005
=6.00

PharmX Technologies's share price for today is A$0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmX Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmX Technologies (ASX:PHX) Business Description

Traded in Other Exchanges
N/A
Address
17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.